news

Freshfields Bruckhaus Deringer, Skadden, Arps, Slate, Meagher & Flom and Han Kun Law Offices have advised Chinese property platform KE Holdings on its listing on the Hong Kong Stock Exchange, with Davis Polk & Wardwell and Jingtian & Gongcheng counselling the joint sponsors.

KE, an integrated online and offline platform for housing transactions and services, has become the second New York-listed company recently to carry out a “listing by introduction” in Hong Kong, according to Reuters, following a similar move by electric vehicle manufacturer Nio Inc in March.

In a listing by introduction, a company does not issue new shares or raise fresh capital, unlike a traditional IPO, Reuters added.

The company’s decision to list on HKSE, which is a dual primary listing, came after KE Holdings was added on April 22 by the U.S. authorities to the list of companies that could be delisted from American exchanges if they did not allow U.S. auditors to access their accounts, Reuters said.

The Freshfields team was led by partners Teresa Ko and David Yi. A team from Harneys advising the issuer on offshore law was led by partners Calamus Huang and Vicky Lord.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

EXPLAINER: How will the updated Company Law help Corporate China?

by Sarah Wong |

Since the enactment of China’s Company Law in 1994, the country’s corporate landscape has taken off in a phenomenal way. To date, more than 40 million companies have been established, and almost 10,000 public companies are listed on the three major stock exchanges.

Freshies counsel joins Simmons as HK regulatory head

UK law firm Simmons & Simmons has announced the appointment of Kenneth Hui as its regulatory head for Hong Kong and Greater China. He was most recently a counsel at Freshfields Bruckhaus Deringer.

Reed Smith, Freshfields, Kirkland on Henlius’ $691 mln take-private deal

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.